{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:50:42Z","timestamp":1787986242257,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,8]]},"DOI":"10.7759\/cureus.81912","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T23:23:26Z","timestamp":1744154606000},"source":"Crossref","is-referenced-by-count":5,"title":["Comparison of Adverse Events Among Angiotensin Receptor Blockers in Hypertension Using the United States Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.7759","author":[{"given":"Toru","family":"Ogura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/ijnrd.s7038","article-title":"Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?","volume":"3","author":"Ripley E","year":"2010","unstructured":"Ripley E, Hirsch A. Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?. Int J Nephrol Renovasc Dis. 2010, 3:93-8. 10.2147\/ijnrd.s7038","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.54311","article-title":"A comparative study of the safety and efficacy between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the management of hypertension: a systematic review","volume":"16","author":"Peresuodei TS","year":"2024","unstructured":"Peresuodei TS, Gill A, Orji C, Reghefaoui M, Saavedra Palacios MS, Nath TS. A comparative study of the safety and efficacy between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the management of hypertension: a systematic review. Cureus. 2024, 16:e54311. 10.7759\/cureus.54311","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0239-7","article-title":"The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases","volume":"38","author":"Abraham HM","year":"2015","unstructured":"Abraham HM, White CM, White WB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf. 2015, 38:33-54. 10.1007\/s40264-014-0239-7","journal-title":"Drug Saf"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(99)00728-6","article-title":"Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?","volume":"84","author":"Unger T","year":"1999","unstructured":"Unger T. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?. Am J Cardiol. 1999, 84:9-15. 10.1016\/s0002-9149(99)00728-6","journal-title":"Am J Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.18.1930","article-title":"Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials","volume":"167","author":"Phillips CO","year":"2007","unstructured":"Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med. 2007, 167:1930-6. 10.1001\/archinte.167.18.1930","journal-title":"Arch Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2023.0153","article-title":"Impact of ACEIs and ARBs-related adverse drug reaction on patients' clinical outcomes: a cohort study in UK primary care","volume":"73","author":"Insani WN","year":"2023","unstructured":"Insani WN, Whittlesea C, Ju C, Man KK, Adesuyan M, Chapman S, Wei L. Impact of ACEIs and ARBs-related adverse drug reaction on patients' clinical outcomes: a cohort study in UK primary care. Br J Gen Pract. 2023, 73:e832-42. 10.3399\/BJGP.2023.0153","journal-title":"Br J Gen Pract"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025950","article-title":"Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction","volume":"135","author":"Messerli FH","year":"2017","unstructured":"Messerli FH, Bangalore S. Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction. Circulation. 2017, 135:2085-7. 10.1161\/CIRCULATIONAHA.116.025950","journal-title":"Circulation"},{"key":"ref8","unstructured":"FDA Adverse Event Reporting System (FAERS) quarterly data extract files. (2025). Accessed. January 31: https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.007476","article-title":"Neoplasm reports in food and Drug Administration Adverse Event Reporting System following angiotensin receptor blocker recalls","volume":"14","author":"Sedgh RC","year":"2021","unstructured":"Sedgh RC, Moon J, Jackevicius CA. Neoplasm reports in food and Drug Administration Adverse Event Reporting System following angiotensin receptor blocker recalls. Circ Cardiovasc Qual Outcomes. 2021, 14:e007476. 10.1161\/CIRCOUTCOMES.120.007476","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1404427","article-title":"Antihypertensive drug-associated adverse events in osteoarthritis: a study of a large real-world sample based on the FAERS database","volume":"15","author":"Guo Z","year":"2024","unstructured":"Guo Z, Di J, Zhang Z, et al.. Antihypertensive drug-associated adverse events in osteoarthritis: a study of a large real-world sample based on the FAERS database. Front Pharmacol. 2024, 15:1404427. 10.3389\/fphar.2024.1404427","journal-title":"Front Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.56418","article-title":"Analysis of adverse events following phenobarbital administration for pediatric patients categorized by one-year age increments using the U.S. Food and Drug Administration Adverse Event Reporting System","volume":"16","author":"Ogura T","year":"2024","unstructured":"Ogura T, Shiraishi C. Analysis of adverse events following phenobarbital administration for pediatric patients categorized by one-year age increments using the U.S. Food and Drug Administration Adverse Event Reporting System. Cureus. 2024, 16:e56418. 10.7759\/cureus.56418","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01242-7","article-title":"Comparison of adverse events occurred during administration of dipeptidyl peptidase-4 inhibitor in patients with diabetes using FDA Adverse Event Reporting System","volume":"43","author":"Ogura T","year":"2023","unstructured":"Ogura T, Shiraishi C. Comparison of adverse events occurred during administration of dipeptidyl peptidase-4 inhibitor in patients with diabetes using FDA Adverse Event Reporting System. Clin Drug Investig. 2023, 43:129-40. 10.1007\/s40261-022-01242-7","journal-title":"Clin Drug Investig"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-019-0754-4","article-title":"Methods to adjust for multiple comparisons in the analysis and sample size calculation of randomised controlled trials with multiple primary outcomes","volume":"19","author":"Vickerstaff V","year":"2019","unstructured":"Vickerstaff V, Omar RZ, Ambler G. Methods to adjust for multiple comparisons in the analysis and sample size calculation of randomised controlled trials with multiple primary outcomes. BMC Med Res Methodol. 2019, 19:129. 10.1186\/s12874-019-0754-4","journal-title":"BMC Med Res Methodol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.34172\/hpp.2023.17","article-title":"Use and outcomes of antihypertensive medication treatment in the US hypertensive population: a gender comparison","volume":"13","author":"Ullah S","year":"2023","unstructured":"Ullah S, Khan S, Bazargan-Hejazi S, et al.. Use and outcomes of antihypertensive medication treatment in the US hypertensive population: a gender comparison. Health Promot Perspect. 2023, 13:140-6. 10.34172\/hpp.2023.17","journal-title":"Health Promot Perspect"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00564","article-title":"Gender differences in cardiovascular pharmacotherapy-the example of hypertension: a mini review","volume":"11","author":"Kalibala J","year":"2020","unstructured":"Kalibala J, Pech\u00e8re-Bertschi A, Desmeules J. Gender differences in cardiovascular pharmacotherapy-the example of hypertension: a mini review. Front Pharmacol. 2020, 11:564. 10.3389\/fphar.2020.00564","journal-title":"Front Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X132730","article-title":"A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension","volume":"22","author":"Palmer AJ","year":"2006","unstructured":"Palmer AJ, Valentine WJ, Tucker DM, et al.. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. Curr Med Res Opin. 2006, 22:2095-100. 10.1185\/030079906X132730","journal-title":"Curr Med Res Opin"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2001.tb11114.x","article-title":"Valsartan alone and as part of combination therapy in general practice in Brazil","volume":"55","author":"Madi JC","year":"2001","unstructured":"Madi JC, Oigman W, Franco R, Armaganijan D. Valsartan alone and as part of combination therapy in general practice in Brazil. Int J Clin Pract. 2001, 55:520-3. 10.1111\/j.1742-1241.2001.tb11114.x","journal-title":"Int J Clin Pract"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.11613\/BM.2009.011","article-title":"The odds ratio: calculation, usage, and interpretation","volume":"19","author":"McHugh ML","year":"2009","unstructured":"McHugh ML. The odds ratio: calculation, usage, and interpretation. Biochem Med. 2009, 19:120-6. 10.11613\/BM.2009.011","journal-title":"Biochem Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222690","article-title":"A method of back-calculating the log odds ratio and standard error of the log odds ratio from the reported group-level risk of disease","volume":"15","author":"Hu D","year":"2020","unstructured":"Hu D, Wang C, O'Connor AM. A method of back-calculating the log odds ratio and standard error of the log odds ratio from the reported group-level risk of disease. PLoS One. 2020, 15:e0222690. 10.1371\/journal.pone.0222690","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81260","article-title":"Comparative analysis of adverse event profiles among seven statins for hypercholesterolemia management using the United States FDA Adverse Event Reporting System","volume":"17","author":"Ogura T","year":"2025","unstructured":"Ogura T, Shiraishi C. Comparative analysis of adverse event profiles among seven statins for hypercholesterolemia management using the United States FDA Adverse Event Reporting System. Cureus. 2025, 17:e81260. 10.7759\/cureus.81260","journal-title":"Cureus"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36525","article-title":"A case report of losartan induced angioedema","volume":"15","author":"Vedantam V","year":"2023","unstructured":"Vedantam V, Magacha HM, Vedantam N, Dahya V, Abu-Heija U. A case report of losartan induced angioedema. Cureus. 2023, 15:e36525. 10.7759\/cureus.36525","journal-title":"Cureus"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2003.12.030","article-title":"Angiotensin II type 2 receptor effect on microvascular hydraulic permeability","volume":"120","author":"Newton CR","year":"2004","unstructured":"Newton CR, Curran B, Victorino GP. Angiotensin II type 2 receptor effect on microvascular hydraulic permeability. J Surg Res. 2004, 120:83-8. 10.1016\/j.jss.2003.12.030","journal-title":"J Surg Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01860.x","article-title":"Blood pressure drug therapy and electrolyte disturbances","volume":"62","author":"Liamis G","year":"2008","unstructured":"Liamis G, Milionis H, Elisaf M. Blood pressure drug therapy and electrolyte disturbances. Int J Clin Pract. 2008, 62:1572-80. 10.1111\/j.1742-1241.2008.01860.x","journal-title":"Int J Clin Pract"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14030756","article-title":"Fluid and electrolyte disorders in traumatic brain injury: clinical implications and management strategies","volume":"14","author":"Tran V","year":"2025","unstructured":"Tran V, Flores J, Sheldon M, Pena C, Nugent K. Fluid and electrolyte disorders in traumatic brain injury: clinical implications and management strategies. J Clin Med. 2025, 14:756. 10.3390\/jcm14030756","journal-title":"J Clin Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(99)80413-5","article-title":"Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipne ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension","volume":"75","author":"Goldberg AI","year":"1995","unstructured":"Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipne ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995, 75:793-5. 10.1016\/s0002-9149(99)80413-5","journal-title":"Am J Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius S","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, et al.. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004, 363:2022-31. 10.1016\/S0140-6736(04)16451-9","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S9434","article-title":"Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program","volume":"7","author":"Abraham I","year":"2011","unstructured":"Abraham I, MacDonald K, Hermans C, Aerts A, Lee C, Bri\u00e9 H, Vancayzeele S. Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program. Vasc Health Risk Manag. 2011, 7:209-35. 10.2147\/VHRM.S9434","journal-title":"Vasc Health Risk Manag"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/01.fjc.0000180902.78230.fd","article-title":"A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker","volume":"46","author":"Mire DE","year":"2005","unstructured":"Mire DE, Silfani TN, Pugsley MK. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol. 2005, 46:585-93. 10.1097\/01.fjc.0000180902.78230.fd","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2174\/1574886314666190307142111","article-title":"Significant weight loss in a patient taking olmesartan: an unusual case report","volume":"14","author":"Makri A","year":"2019","unstructured":"Makri A, Florentin M, Elisaf MS, Liamis G. Significant weight loss in a patient taking olmesartan: an unusual case report. Curr Drug Saf. 2019, 14:238-41. 10.2174\/1574886314666190307142111","journal-title":"Curr Drug Saf"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.36468\/pharmaceutical-sciences.1402","article-title":"Drug-induced gastroesophageal reflux disease: a disproportionality analysis of food and Drug Administration\u2019s Adverse Event Reporting System","volume":"86","author":"Chen Y","year":"2024","unstructured":"Chen Y, Yang M. Drug-induced gastroesophageal reflux disease: a disproportionality analysis of food and Drug Administration\u2019s Adverse Event Reporting System. Indian J Pharm Sci. 2024, 86:1355-62. 10.36468\/pharmaceutical-sciences.1402","journal-title":"Indian J Pharm Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/352710-comparison-of-adverse-events-among-angiotensin-receptor-blockers-in-hypertension-using-the-united-states-food-and-drug-administration-adverse-event-reporting-system","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T23:23:29Z","timestamp":1744154609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/352710-comparison-of-adverse-events-among-angiotensin-receptor-blockers-in-hypertension-using-the-united-states-food-and-drug-administration-adverse-event-reporting-system"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.81912","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,8]]}}}